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Abstract
Background and aim: The effect of vitamin D supplementation on immune disorders has been a
topical research focus. The aim of this systematic review was to examine the current evidence of
the effect of vitamin D supplementation as a therapy for colitis.
Methods: The following databases were searched: MEDLINE, Pubmed, Scopus, Web of Knowl-
edge, Cinicaltrials.gov and the Cochrane Central Register of Controlled Trials using the terms
‘inflammatory bowel disease’ ‘Crohn's disease’ ‘ulcerative colitis’ ‘colitis’ [and] ‘vitamin D’.
Both human and animal studies published in English language were examined. The reference
lists of included studies and review articles were manually searched for any relevant studies.
Results: Four studies were included in this systematic review. All reported an improvement in
disease activity with vitamin D supplementation. The only high quality human study reported
a non-significant reduction of relapse rate for Crohn's disease. No major adverse effects of vita-
min D supplementation were reported.
Conclusions: Although there is some evidence that supplemental vitamin D, as an adjunctive treat-
ment, may help in controlling colitis, this evidence is not enough to justify using vitamin D in treat-
ing inflammatory bowel disease (IBD). Large high quality placebo-controlled randomised controlled
trials are needed to explore a possible benefit of using vitamin D in treating IBD.
Crown Copyright © 2012 Published by Elsevier B.V. on behalf of European Crohn's and Colitis
Organisation. Open access under CC BY-NC-ND license.40 Sherbrook St., Winnipeg, M
.ca (W. El-Matary).
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Vitamin D is very important in calcium homeostasis, controlling
the formation and resorption of bone.1 The immune-related
function of vitamin D was not discovered until the 1980s. The
identification of vitamin D receptors on peripheral bloodmono-
nuclear cells in 1983 sparked the interest in a possible role of
vitamin D in the immune system.1,2 Vitamin D is acknowledged
as an immune system regulator.3 T-Cell mediated immunity is
under modulatory control of 1,25dihydroxycholcecalciferol,
the active form of vitamin D.4,5 The absence of vitamin D was
shown to blunt the T-cell mediated immune responses. At
very high doses of vitamin D, this effect recurred.3
Stores of vitamin D in the body comprise vitamin D2 and
vitamin D3. Most body stores come from vitamin D3 which
is synthesised by the direct action of sunlight on the skin.6
A small proportion of total vitamin D is obtained from the
diet, which is known as vitamin D2. This is mainly obtained
from fish oil or as a direct supplementation. Few food ele-
ments are naturally rich in vitamin D, so its levels depend
on sunlight exposure or supplementation to be replenished.6
The zenith angle of the sun determines the amount of D3
produced in the skin.3,6 Geographical latitude, season and
time of day affect this angle. Countries in northern climates
receive an oblique angle in autumn and winter. Such an
angle precludes the production of vitamin D3.6,7
Inflammatory bowel disease (IBD), an immune mediated
disease of unknown aetiology that affects the gastrointesti-
nal tract, is most prevalent in northern climates such as
North America and Northern Europe.8 There are two distinct
forms of IBD — Crohn's disease (CD) and ulcerative colitis
(UC).8 The pathogenesis of IBD involves a complex interplay
between genetic, environmental and immunological fac-
tors.9 It has been determined that in both forms of IBD, the
tissue damage results from an inappropriate or exaggerated
immune response to luminal antigens of gut microflora. T
cells overproduce inflammatory mediators like interleukin-
17 (IL-17), tumour necrosis factor α (TNF α) and interferon
gamma (IFN-Ý).10 The tissue damage occurs in areas that
are heavily infiltrated with activated CD4+ lymphocytes.11
A recent hypothesis linking vitamin D deficiency to devel-
opment of immune-related disorders has been proposed.
This argues that decreased outdoor activity and vitamin D
poor diets have led to fluctuations in vitamin D status in de-
veloped countries, particularly those that experience long
winter seasons.12,13 For people living in northern climates,
vitamin D deficiency is relatively common.14 In particular,
patients with IBD are likely to have a high incidence ofhypovitaminosis D.15 This could be due to a number of differ-
ent mechanisms, including decreased intestinal absorption,
increased intestinal loss through a protein losing enteropa-
thy, and decreased exposure to sunlight. This has led some
to believe that vitamin D deficiency may play a role in the
pathogenesis of IBD.3
There is a mounting evidence for a link between vitamin D
availability either from the sunshine or diet and other auto-
immune diseases.16 Finland has the highest rates of type 1 di-
abetes in the world.17 A Finnish study involving over 12,000
children, showed vitamin D supplementation decreased the
risk of type 1 diabetes mellitus by 80%.17 Multiple sclerosis
(MS) is similarly most prevalent in countries far from the
equator, with a particularly high incidence in Scotland.18 Vi-
tamin D deficiency is common in patients with MS.3 Women
with the highest vitamin D intakes had a 40% reduction in
risk of developing MS.19 Clinical improvement of patients
with rheumatoid arthritis was strongly associated with high
dose vitamin D.20
The aim of this systematic review was to examine the ev-
idence assessing the effect of vitamin D for treating colitis in
humans and experimental colitis in animals, i.e. idiopathic
and experimental inflammatory bowel disease.2. Materials and methods
2.1. Search strategy and eligibility criteria
Using the terms “COLITIS”, “CROHNS”, “INFLAMMATORY
BOWEL DISEASE” [and] “VITAMIN D” the following databases
were searched for relevant papers: MEDLINE (1966 — Week 1
July 2011); Pubmed (1950 —Week 1 July 2011); Scopus; Web
of Knowledge; clinicaltrials.gov and the Cochrane Central
Register of Controlled Trials (CENTRAL). In addition, the ref-
erence lists of all included studies and review articles were
reviewed for relevant citations.2.1.1. Inclusion criteria
All human (any age) and animal randomised controlled
(RCT) and cohort studies specifically investigating the effect
of vitamin D supplementation on disease activity in colitis
(either inducing or maintaining remission), regardless
serum levels of vitamin D. Disease activity was assessed
using any indices in humans or examination of the colon
with experimental colitis in animals. Only studies written
in the English language were included.
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Studies in any language other than English, case reports,
case series, studies which examined the role of vitamin D in
the bone mineral density of IBD sufferers, studies looking
into the effect of vitamin D receptors on disease activity, ob-
servational studies commenting on vitamin D level in IBD pa-
tients, but not intervening with supplements. Review articles
were also excluded, as were abstracts.
2.1.3. Primary outcome and reporting the PICO formula
P (Participants: Patients of any age with colitis or animals
with experimental colitis). I (Interventions: vitamin D sup-
plementation). C (Comparisons: Patients with colitis or ani-
mals with experimental colitis on placebo, any medication
or no vitamin D). O (Outcome (primary): inducing or main-
taining remission of the disease). Secondary outcome was
any reported adverse effects of vitamin D in human studies.
2.2. Data extraction and quality assessment
Retrieved articles were screened based on title and then ab-
stract content by one author (IN) and categorised into ‘in-
clude’, ‘possible’ and ‘exclude’. Where available, the full
texts of the ‘include’ and ‘possible’ were obtained and
assessed independently by the two authors (IN and WE). Any
disagreement was resolved through a consensus discussion
and consulting a third author (AMD). During the process of
quality assessment, none of the authors were blinded as to
any of the following: the authors, journal, institution, year
of publication or results. Quality assessment of each study
was carried out using Jadad and Higgins criteria for RCTs.21,22
3. Results
The literature search algorithm is summarised in Fig. 1. The
characteristics of the included and excluded studies are
summarised in Tables 1–3. Four studies were included23–26:
two included human participants (Table 1) and the otherSTUDIES INCLUDED BASED 
ON TITLE 191
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2
STUDIES UNSURE
3
FINAL STUDIES
INCLUDED
4
STU
INC
Figure 1 Algorithm otwo included experimental animals (Table 2). All four stud-
ies showed some benefits to use the vitamin D supplements.
However, only two studies had results which achieved statis-
tical significance. The only double-blinded RCT which was of
a good quality examined the effect of supplemental vitamin
D3 in maintaining (rather than inducing) remission for
Crohn's disease.26 Compared to placebo, the study reported
a non-significant reduction of relapse rate at the end of
12 months (29% vs. 13%, p=0.06). There were no reported
adverse effects directly attributable to vitamin D.26
The other human study looked into the effect of 2 differ-
ent forms of vitamin D on Crohn's disease activity (and bone
markers).25 One form of vitamin D was superior in maintain-
ing disease remission compared to the other form at the end
of 6 weeks of the trial but not at the end of 12 months.25 The
study did not address adverse events of vitamin D.25
Two animal studies were included in this review (Table 3).
Both studies showed a significant effect of vitamin D on exper-
imental colitis.23,24 In the study by Cantorna et al., interleukin
10 knockout (IL-10 KO) mice were given 0.005 mcg of 1,25-
dihydroxycholecalciferol. Over a four-week period, IBD symp-
toms significantly (Pb0.05) improved, compared to a cohort
of vitamin D naive mice. Vitamin D deficient mice rapidly de-
veloped diarrhoea and a wasting disease, which induced mor-
tality.23 In contrast, supplementation with 50 IU significantly
ameliorated symptoms of IBD in the mice. A separate group
was given higher levels of vitamin D (0.2 mcg). This blocked
the progression and ameliorated the (Pb0.05) symptoms in
the IL 10-KO mice after just two weeks.23 This suggests a posi-
tive correlation between level of supplementation and speed
of disease-reducing action. The small intestines of deficient an-
imals were significantly heavier than those supplemented, at
9.9% of total body weight. This is a remarkable result of more
than double the expected proportion in a typical mice
population. There were no significant differences in the overall
body weight of the mice in the intervention and control
group.23
Daniel et al. examined whether the vitamin D analogue
22-Ene-25-Oxa-vitamin D has a comparable efficacy toSTUDIES EXCLUDED
BASED ON
ABSTRACT 178
STUDIES EXCLUDED
9
DIES
LUDED 2
STUDIES EXCLUDED
1
f literature search.
Table 1 Characteristics of included studies: human.
Study N Mean
disease
duration
Methodology Purpose Intervention Assessment Definiti of
improve nt
Conclusions Quality assessment
Miheller
et al.25
37 9.6 years Single
centre
cohort
Compare effects
of 1,25 dihydroxyvitamin
and 25 hydroxyvitamin D
on bone pathology
and disease activity
in CD patients
Group A given ‘active’ vitamin
D3 — 2×0.25 mcgs alfacalcidol/day.
Group B given ‘plain’ vitamin
D3 — 1000 IU cholecalciferol/day.
CDAI Signific
reducti n
disease
activity
measur by
CDAI, C
and SIB
Significant
differences
shown at 6 weeks
but these
disappeared by
12th month
Open label
Small cohort
Jorgensen
et al.26
94 7 years Multi-centre
randomised
double
blinded
placebo
controlled
trial
Assess the effect of
vitamin D3 as adjunctive
agent compared to place
in maintaining remission
CD, and its effect on seru
levels of Vitamin D
One group given 1200 IU vitamin
D3+1200 mg calcium/day
One group given
placebo+1200 mg calcium/day
CDAI CDAI of 0+
and an
increas
CDAI of
compar to
baseline
1200 IE
supplements
increased
vitamin D levels
but did not
significantly
reduce relapse
rate
Good double blind
randomization
process with adequate
sequence generation.
Allocation concealment
is not clear.
Adequate description of
dropouts.
Table 2 Characteristics of included studies: mice models.
Study Number
of
animals
Method of
inducing colitis-
like state
Purpose of study Int ntion Assessment of
disease activity
Conclusio Quality
assessment
Cantorna
et al.23
36 Transgenic
breeding of
Interleukin 10-
knockout mice
Compare vitamin D
deficiency and vitamin
D sufficient mice to
disease activity
No min D vs.
0.0 mcgs/d calcitriol
No min D vs.
0.2 g/d calcitriol
-Colon weight
-Histological exam of colon
-Body mass
Vitamin D gnificantly ameliorated symptoms.
Higher d of calcitriol acted quicker to
decrease tivity.
Animal
study
Daniel et
al.24
Not
stated
2,4,6-
trinitrobenzene
sulfonic acid
(TNBS) rectal
enema
Compare efficacy of
vitamin D analogue
(ZK156979) with 1,25-
dihydroxyvitamin D
0.1 0 mcgs/kg body
we ZK156979 vs
0.2 gs/kg body weight
cal iol
-Macroscopic exam of colon
-Histological exam of colon
-Colon length
-Colon weight
-Body mass
-Stool consistency
-Quantity of rectal bleeding
Vitamin nalogue (ZK1569790) is as potent
as 1,25-d droxyvitamin D. It does not induce
hypercal mia. Both substances significantly
reduce d ase activity.
Animal
study
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Table 3 Characteristics of excluded studies.
Study Design Outcome Reason for Exclusion
Harries et al.27 Observational Under-nourished CD patients have low vitamin D levels Not interventional, measures vitamin D levels
Ginanjar et al.28 Review article Some studies show that vitamin D inhibits induction of
autoimmune encephalomyelitis, thyroiditis, type-1
diabetes mellitus, inflammatory bowel disease (IBD),
systemic lupus erythematosus, and collagen-induced
arthritis and Lyme arthritis
Review article
Froicu et al .29 Experimental model VDR deficiency accelerated the development of
experimental IBD in mice
Receptor status investigated, not vitamin D levels
Utilisky et al.15 Retrospective cohort study Vitamin D deficiency is common in IBD and is independently
associated with lower HRQOL and greater disease activity in CD.
Observational, did not give supplements but
measured vitamin levels.
El Matary et al.30 Cross sectional analytical
study
Vitamin D levels are not affected by disease severity Cross sectional, not interventional, no supplements
given.
Cantorna3 Review article Autoimmune diseases like IBD and MS are acutely affected
by vitamin D status and vitamin D receptor signalling.
Review article
Gilman et al.31 Cross sectional observational
study
High proportion of CD patients have vitamin D deficiency Cross sectional observational — no supplements given
Leslie et al.32 Cohort study A minority of recently diagnosed IBD patients would have
an optimal vitamin D serum levels which correlated
with bone mineral density.
No intervention or vitamin D supplement s given
Stio et al.33 In-vitro study T lymphocyte proliferation was inhibited in the presence of
vitamin D and two vitamin D analogues — EB 1089 and KH 1060.
In vitro study
Not a human or animal study
Cantorna34 Review article Mechanisms underlying the effect of vitamin D on the
immune system.
In the absence of vitamin D and the VDR, autoimmunity occurs
in the gastrointestinal tract due to increased numbers of IL-17
and IFN-γ secreting T-cells and a concomitant reduction in
regulatory T-cells
Review article
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410 I. Nicholson et al.active vitamin D. The analogue clearly reduced the severity
of TNBS-induced colitis without hypercalcemic side effects
seen on occasion with the use of vitamin D itself. This oc-
curred with potency comparable to calcitriol.24 Significant
improvement was shown in weight gain, a decrease in clini-
cal activity score, and the amelioration of macroscopic
signs of colitis.244. Discussion
The vitamin D supplementation in the treatment of some
immune-related diseases is increasing. However, its role in
the treatment of IBD is unclear. Four studies fulfilled the in-
clusion criteria of this systematic review. Two animal studies
found that vitamin D had a statistically significant effect on
disease activity of experimental colitis.23,24 Two human
studies documented some benefits of supplemental vitamin
D in maintaining remission of Crohn's disease.25,26
Jorgensen et al. showed a robust method in a randomised
double-blinded placebo controlled trial.26 Although sample
size calculation was provided, one could argue that statisti-
cal significance was not achieved due to type II statistical
error.
Miheller et al. compared 2 different forms of vitamin D.25
A significant decrease in Crohn's Disease Activity Index
(CDAI) scores and CRP was shown 6 weeks into the trial.
These differences in disease activity disappeared by
12 months (the end of the trial).25 The trial was comparing
active to plain vitamin D, rather than vitamin D to placebo.
Therefore, the absence of sustained significance in differ-
ences did not undermine efficacy of vitamin D, but rather
additional benefit gained by using an active form of it.
Quality of life information was available in the paper by
Miheller et al. through the use of a HRQOL questionnaire.25
This allowed an extra dimension to the measurement of ac-
tivity of IBD to be assessed. Quality of life, like disease activ-
ity, improved significantly in the short term (6 weeks) but
not in the long term. This trial was not blinded so it is
debateable how accurate this information is. Such QOL as-
sessment was not made in Jorgensen's study.26
It was not clear in these 2 studies the extent of sunlight
exposure that the patients had. Variations in lifestyle and
occupation of participants would have led to a disparity in
the amount of sunlight received by patients.
No human studies looking at the effect of vitamin D sup-
plementations in achieving remission of IBD or maintaining
remission in ulcerative colitis were found. No study showed
that vitamin D or analogue supplementations are harmful
to the participants or worsen their colitis. This indicates
that they are both well tolerated.
The studies involving an experimental model of IBD in
mice showed a reduction in disease activity that achieved
statistical significance. However, the control over the
amount of vitamin D the mice were able to synthesise dif-
fered between the studies. In the paper by Cantorna et al.,
pregnant mice of 2 weeks gestation were deprived of vita-
min D. This ensured that their offspring would be completely
vitamin D deficient by week 5 of age, at entry to the study.
In addition to this, trial mice were housed under ‘yellow
light,’ which prevented the synthesis of vitamin D through
their skin.23 In contrast, the mice used in the study by Danielet al. were not the offspring of vitamin D deprived mothers
and were fed “standard mouse chow” from birth.24 Although
they were kept in a controlled environment, they were not
kept under yellow light. As a consequence, they would
have been able to synthesise vitamin D3 through their skin.
Different methods were used to induce IBD in rodents.
Daniel et al. induced colitis at the beginning of the experi-
ment through rectal enemas of 2,4,6-trinitobenzenesulfonic
acid (TNBS).23 In contrast, Cantorna et al. used Interleukin-
10 knockout transgenic mice (Il-10 KO) raised in specific
pathogen free facilities.24 These mice had endured symp-
toms of IBD from birth. Perhaps one could argue that the
transgenic mice represent the chronic nature of IBD more re-
liably than a TNBS-induced model.
The results from animal studies are of course limited in
their application to the human species. Nonetheless, exper-
imental models are an important foundation for establishing
relationships between interventions and disease activity.
A thorough literature search was conducted for this sys-
tematic review. All relevant references cited in included
studies were followed ensuring all relevant published re-
search was included. The limitations of this review include
the paucity of the studies included. Nonetheless, this high-
lights the strong need for well-planned and conducted
studies addressing this objective. The role of vitamin D in
managing IBD should be addressed not only in achieving re-
mission of active IBD but also in maintaining remission. Im-
portant factors that could affect the outcome like the
dose, route, and duration of treatment of vitamin D should
be explored. Moreover, serum level of vitamin D before
and during therapy should be carefully examined.
Neither of the human studies included patients suffering
from UC. Arguably the results of the review do not fairly re-
flect both forms of IBD. Further research involving UC partic-
ipants would be beneficial. The results of all four studies are
limited by small sample size. In the two human studies a
total of 141 participants were included.25,26
Further limitations include the exclusion of non-English
studies and being unable to include unpublished work and
grey literature. One would hope that at some point there
will be established methods to access unpublished studies.
Attempts were made in this review to contact the authors
of one unpublished study but a reply was not received.5. Conclusions and recommendations
There is some evidence from human studies that vitamin D
supplementations may help in maintaining remission for
Crohn's disease. However the results appear significant in
murine models of experimental colitis. The public health im-
plications, of a possible link between vitamin D and IBD, war-
rant further funding for research into this area. Large, multi-
centre double-blinded placebo controlled trials are needed
to determine further the effects of vitamin D on the disease
activity of IBD. The effect of vitamin D supplementation
should be evaluated not only on establishing remission but
also on maintaining remission of IBD.
Currently, there are a number of on-going clinical trials
that are addressing this topic. This holds promise that in the
future we will have a better evidence for supporting the use
of vitamin D supplementation in the treatment of IBD.
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